Ken Griffin
CRNX icon

Ken Griffin’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ken Griffin’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5M Buy
317,934
+63,214
+25% +$2.82M ﹤0.01% 3055
2025
Q4 		$11.9M Sell
254,720
-629,787
-71% -$28M ﹤0.01% 3036
2025
Q3 		$36.8M Buy
884,507
+230,872
+35% +$7.38M 0.01% 1679
2025
Q2 		$18.8M Buy
653,635
+615,084
+1,596% +$19M ﹤0.01% 2221
2025
Q1 		$1.29M Buy
38,551
+33,829
+716% +$1.26M ﹤0.01% 6380
2024
Q4 		$241K Sell
4,722
-130,412
-97% -$7.3M ﹤0.01% 10100
2024
Q3 		$6.91M Buy
135,134
+13,255
+11% +$684K ﹤0.01% 3441
2024
Q2 		$5.46M Sell
121,879
-49,545
-29% -$2.29M ﹤0.01% 3609
2024
Q1 		$8.02M Buy
171,424
+148,632
+652% +$5.82M ﹤0.01% 3235
2023
Q4 		$811K Sell
22,792
-136,444
-86% -$4.18M ﹤0.01% 7109
2023
Q3 		$4.74M Sell
159,236
-82,492
-34% -$1.7M ﹤0.01% 3735
2023
Q2 		$4.36M Sell
241,728
-43,867
-15% -$875K ﹤0.01% 3854
2023
Q1 		$4.59M Buy
285,595
+248,239
+665% +$4.59M ﹤0.01% 3960
2022
Q4 		$684K Sell
37,356
-2,855
-7% -$50.3K ﹤0.01% 7589
2022
Q3 		$790K Buy
+40,211
New +$820K ﹤0.01% 7493
2022
Q2 		– Sell
-49,839
Closed -$995K – 13013
2022
Q1 		$1.09M Sell
49,839
-14,985
-23% -$303K ﹤0.01% 7493
2021
Q4 		$1.84M Buy
64,824
+27,605
+74% +$681K ﹤0.01% 6437
2021
Q3 		$783K Sell
37,219
-23,439
-39% -$490K ﹤0.01% 8761
2021
Q2 		$1.14M Buy
+60,658
New +$1.07M ﹤0.01% 8007
2021
Q1 		– Sell
-46,864
Closed -$661K – 13218
2020
Q4 		$661K Buy
46,864
+7,762
+20% +$108K ﹤0.01% 7611
2020
Q3 		$613K Buy
39,102
+6,076
+18% +$92.9K ﹤0.01% 6924
2020
Q2 		$579K Sell
33,026
-2,711
-8% -$46.2K ﹤0.01% 6809
2020
Q1 		$526K Buy
35,737
+7,809
+28% +$160K ﹤0.01% 6383
2019
Q4 		$701K Buy
27,928
+295
+1% +$5.62K ﹤0.01% 6234
2019
Q3 		$416K Buy
27,633
+15,839
+134% +$308K ﹤0.01% 7067
2019
Q2 		$295K Buy
+11,794
New +$292K ﹤0.01% 7609

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ken Griffin's CRNX Position: Q1 2026 in Review

Ken Griffin increased its Crinetics Pharmaceuticals (CRNX) stake by 25% in Q1 2026, buying an estimated $2.82M and bringing the position to 317,934 shares worth $11.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3055.

Ken Griffin first reported a position in CRNX in Q2 2019 and has held it in 26 quarters since. The position peaked at $36.8M in Q3 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Ken Griffin held 317,934 shares of Crinetics Pharmaceuticals worth $11.5M as of Q1 2026.
  • Ken Griffin bought 63,214 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $2.82M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #3055 holding.
  • Ken Griffin first reported a position in Crinetics Pharmaceuticals in Q2 2019 and has held it in 26 quarters since.
  • Ken Griffin's Crinetics Pharmaceuticals position peaked at $36.8M in Q3 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.